Genomic Health (NASDAQ:GHDX) Stock Rating Reaffirmed by Barclays

Genomic Health (NASDAQ:GHDX)‘s stock had its “sell” rating restated by investment analysts at Barclays in a research report issued to clients and investors on Monday, January 8th. They currently have a $28.00 price objective on the medical research company’s stock. Barclays’ price target would indicate a potential downside of 19.10% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity reiterated a “buy” rating and set a $35.00 price target on shares of Genomic Health in a research note on Wednesday, September 27th. ValuEngine lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. William Blair lowered shares of Genomic Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Finally, Jefferies Group reissued a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a research report on Friday, October 20th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $32.14.

Shares of Genomic Health (NASDAQ:GHDX) traded down $0.79 during midday trading on Monday, reaching $34.61. 116,178 shares of the company traded hands, compared to its average volume of 170,360. Genomic Health has a one year low of $26.37 and a one year high of $37.50. The stock has a market cap of $1,231.40, a PE ratio of -288.42 and a beta of 0.66.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Wednesday, November 8th. The medical research company reported $0.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.04. Genomic Health had a negative net margin of 1.30% and a negative return on equity of 1.79%. analysts predict that Genomic Health will post -0.08 EPS for the current year.

In related news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $31.47, for a total value of $157,350.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. Insiders sold 65,717 shares of company stock valued at $2,158,232 in the last quarter. Company insiders own 46.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Aurora Investment Counsel acquired a new position in shares of Genomic Health in the fourth quarter valued at approximately $1,879,000. Public Employees Retirement System of Ohio acquired a new position in shares of Genomic Health in the third quarter valued at approximately $444,000. GSA Capital Partners LLP raised its position in shares of Genomic Health by 43.7% in the third quarter. GSA Capital Partners LLP now owns 63,100 shares of the medical research company’s stock valued at $2,025,000 after buying an additional 19,200 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Genomic Health in the third quarter valued at approximately $138,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Genomic Health in the third quarter valued at approximately $350,000. Institutional investors own 89.83% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/01/17/genomic-healths-ghdx-sell-rating-reaffirmed-at-barclays.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply